• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

营养状况与常染色体显性多囊肾病患者的肾功能保留相关。

Nutritional Status is Associated With Preserved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease.

机构信息

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.

Department of Internal Medicine, Hallym University College of Medicine, Seoul, South Korea.

出版信息

J Ren Nutr. 2023 Jul;33(4):529-537. doi: 10.1053/j.jrn.2023.02.006. Epub 2023 Mar 24.

DOI:10.1053/j.jrn.2023.02.006
PMID:36965751
Abstract

OBJECTIVE

Malnutrition is a common complication in autosomal dominant polycystic kidney disease (ADPKD). We examined whether nutritional status is associated with the preservation of kidney function, using a cohort of typical ADPKD.

METHODS

We enrolled ambulatory ADPKD patients in 9 tertiary medical centers in Korea from May 2019 to December 2021. We excluded patients who were aged less than 18 years, who had known end-stage kidney disease at the time of enrollment, who had a diagnosis of atypical ADPKD, and who were Tolvaptan users. The primary outcome was an estimated glomerular filtration rate (eGFR) decline >3 mL/min/1.73 m, based on nutritional status assessed by subjective global assessment (SGA). We also evaluated an eGFR decline >1 mL/min/1.73 m, an increase in urine protein-creatinine ratio (UPCR) > 0, and an increase in UPCR >0.3 as secondary outcomes, based on SGA after the 1-year follow-up. A logistic regression (LR) model was used to calculate the odds ratio (OR) for the primary outcome. Because there were differences in several baseline variables, such as Mayo classification, serum hemoglobin, serum creatinine, and UPCR between SGA groups, we matched propensity scores.

RESULTS

In total, 805 patients were prospectively enrolled. Among them, 236 patients who had 1-year follow-up data and typical imaging findings were analyzed to evaluate the effect of nutritional status on kidney function. SGA was used to assess the nutritional status. The mean age was 45.0 ± 13.3 years, and 49.6% of the patients were female. The mean eGFR was 81.9 mL/min/1.73 m. Among the 236 patients, 91 (38.6%) experienced a 1-year eGFR decline >3 mL/min/1.73 m. When a multivariable LR was applied, SGA 3-6 was identified as a significant factor related to a 1-year eGFR decline >3 mL/min/1.73 m (adjusted OR = 1.22 [1.04-1.43]; P = .017). Despite matching propensity scores, the 1-year eGFR decline >3 mL/min/1.73 m was still higher in the SGA 3-6 group regardless of proteinuria.

CONCLUSION

Good nutritional status is associated with better-preserved kidney function in non-obese typical ADPKD patients who do not take Tolvaptan.

摘要

目的

营养不良是常染色体显性多囊肾病(ADPKD)的常见并发症。我们通过一组典型的 ADPKD 患者来研究营养状况是否与肾功能的保留有关。

方法

我们从 2019 年 5 月至 2021 年 12 月在韩国的 9 个三级医疗中心招募了门诊 ADPKD 患者。我们排除了年龄小于 18 岁、入组时已患有终末期肾病、诊断为非典型 ADPKD 以及使用托伐普坦的患者。主要结局是根据主观整体评估(SGA)评估的营养状况,估计肾小球滤过率(eGFR)下降>3 mL/min/1.73 m。我们还根据 SGA 评估了 1 年后的次要结局,包括 eGFR 下降>1 mL/min/1.73 m、尿蛋白/肌酐比(UPCR)增加>0.0 和 UPCR 增加>0.3。使用逻辑回归(LR)模型计算主要结局的优势比(OR)。由于 SGA 组之间存在几个基线变量(如 Mayo 分类、血清血红蛋白、血清肌酐和 UPCR)的差异,我们进行了倾向评分匹配。

结果

总共前瞻性纳入了 805 名患者。其中,236 名患者具有 1 年随访数据和典型影像学表现,用于评估营养状况对肾功能的影响。使用 SGA 评估营养状况。患者的平均年龄为 45.0±13.3 岁,49.6%为女性。平均 eGFR 为 81.9 mL/min/1.73 m。在 236 名患者中,91 名(38.6%)在 1 年内 eGFR 下降>3 mL/min/1.73 m。当应用多变量 LR 时,SGA 3-6 被确定为与 1 年内 eGFR 下降>3 mL/min/1.73 m 相关的显著因素(调整后的 OR=1.22[1.04-1.43];P=0.017)。尽管进行了倾向评分匹配,但无论蛋白尿如何,SGA 3-6 组的 1 年内 eGFR 下降>3 mL/min/1.73 m 仍然更高。

结论

在不服用托伐普坦的非肥胖典型 ADPKD 患者中,良好的营养状况与更好的肾功能保留有关。

相似文献

1
Nutritional Status is Associated With Preserved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease.营养状况与常染色体显性多囊肾病患者的肾功能保留相关。
J Ren Nutr. 2023 Jul;33(4):529-537. doi: 10.1053/j.jrn.2023.02.006. Epub 2023 Mar 24.
2
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.托伐普坦治疗常染色体显性遗传多囊肾病的长期疗效观察。
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19.
3
Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性多囊肾病患者时与总肾体积增长率无关的肾功能保存。
Clin Exp Nephrol. 2021 May;25(5):467-478. doi: 10.1007/s10157-020-02009-0. Epub 2021 Jan 20.
4
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.托伐普坦在不同慢性肾脏病阶段对常染色体显性遗传性多囊肾病的疗效:TEMPO 3:4试验结果
Clin J Am Soc Nephrol. 2016 May 6;11(5):803-811. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23.
5
Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.托伐普坦治疗日本晚期常染色体显性遗传性多囊肾病患者的效果。
J Nephrol. 2018 Dec;31(6):961-966. doi: 10.1007/s40620-018-0545-8. Epub 2018 Oct 24.
6
Effectiveness of tolvaptan on renal replacement therapy in patients with autosomal dominant polycystic kidney disease: a retrospective cohort study from the TriNetX global collaborative network.托伐普坦治疗常染色体显性多囊肾病患者肾脏替代治疗的效果:来自 TriNetX 全球合作网络的回顾性队列研究。
Ren Fail. 2024 Dec;46(2):2412721. doi: 10.1080/0886022X.2024.2412721. Epub 2024 Oct 18.
7
Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease.对于常染色体显性多囊肾病门诊患者,全肾和肝脏体积是营养不良的主要危险因素。
BMC Nephrol. 2017 Jan 14;18(1):22. doi: 10.1186/s12882-016-0434-0.
8
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.托伐普坦治疗对常染色体显性多囊肾病肾功能下降的长期益处建模:使用常染色体显性多囊肾病结局模型的探索性分析
BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5.
9
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.托伐普坦对不同肾功能水平常染色体显性多囊肾病个体的短期疗效。
Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.
10
Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.内脏脂肪与常染色体显性多囊肾病的进展:来自TEMPO 3:4试验患者的队列研究
Am J Kidney Dis. 2024 Sep;84(3):275-285.e1. doi: 10.1053/j.ajkd.2024.02.014. Epub 2024 Apr 10.

引用本文的文献

1
Nutritional considerations for designing ketogenic dietary interventions for people with Autosomal Dominant Polycystic Kidney Disease.为常染色体显性多囊肾病患者设计生酮饮食干预措施时的营养考量
J Nephrol. 2025 Aug 10. doi: 10.1007/s40620-025-02378-3.
2
Body water distribution, early malnutrition and sarcopenia in ADPKD: insights from a cross sectional study.常染色体显性多囊肾病患者的身体水分分布、早期营养不良与肌肉减少症:一项横断面研究的见解
J Nephrol. 2025 Jul 22. doi: 10.1007/s40620-025-02327-0.
3
The Role of Adiposity and Anthropometrics on Disease Progression in Autosomal Dominant Polycystic Kidney Disease: A Narrative Review.
肥胖和人体测量学指标在常染色体显性多囊肾病疾病进展中的作用:一项叙述性综述
Curr Nutr Rep. 2025 Apr 7;14(1):56. doi: 10.1007/s13668-025-00650-3.
4
Advances in sarcopenia and urologic disorders.肌肉减少症与泌尿系统疾病的研究进展。
Front Nutr. 2024 Nov 6;11:1475977. doi: 10.3389/fnut.2024.1475977. eCollection 2024.
5
Baseline characteristics of the Korean genetic cohort of inherited cystic kidney disease.韩国遗传性囊性肾病基因队列的基线特征。
Kidney Res Clin Pract. 2023 Sep;42(5):617-627. doi: 10.23876/j.krcp.23.097. Epub 2023 Sep 27.